GLP-1 & Incretin Science

Semaglutide vs Tirzepatide: What the Direct Comparison Showed

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

SURMOUNT-5 compared the two directly over 72 weeks in 751 adults with obesity and without diabetes. Tirzepatide produced 20.2% mean weight reduction against semaglutide's 13.7%, with greater waist reduction and fewer gastrointestinal discontinuations. Semaglutide retains the larger cardiovascular outcome evidence base.

Key facts

Trial
SURMOUNT-5, 751 adults, 72 weeks
Tirzepatide result
−20.2% (22.8 kg)
Semaglutide result
−13.7% (15.0 kg)
Waist circumference
−18.4 cm vs −13.0 cm
GI discontinuation
2.7% vs 5.6%
Doses compared
Max tolerated: 10/15 mg vs 1.7/2.4 mg
Significance
p<0.001 on both endpoints

Why this trial settles more than cross-trial comparison could

Most comparisons in this field are indirect: one drug's trial against another drug's trial, with different populations, durations and estimands. SURMOUNT-5 randomised the same population to both drugs at the same time for the same duration, which removes almost every confound that makes indirect comparison unreliable. It is the strongest evidence available on this question.

The headline result

Over 72 weeks, tirzepatide produced 20.2% mean weight reduction, averaging 22.8 kg, against semaglutide's 13.7%, averaging 15.0 kg. Both arms used the maximum tolerated dose: 10 or 15 mg for tirzepatide, 1.7 or 2.4 mg for semaglutide. Tirzepatide participants were also more likely to reach every threshold from 10% through 25%.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Body composition and cardiometabolic measures

Waist circumference fell 18.4 cm on tirzepatide against 13.0 cm on semaglutide. Tirzepatide also produced significantly greater improvement in systolic and diastolic blood pressure, HbA1c, fasting insulin, triglycerides and HDL cholesterol at 72 weeks.

The tolerability finding is the counterintuitive one

Larger effect usually costs tolerability across this class. Here it did not. Gastrointestinal adverse events causing discontinuation occurred in 2.7% on tirzepatide against 5.6% on semaglutide, so the more effective drug was also the better tolerated one on that measure. This is a real exception to the pattern that holds almost everywhere else in incretin pharmacology.

What semaglutide still has

Outcome data. SELECT enrolled 17,604 participants and demonstrated a 20% reduction in major adverse cardiovascular events, and semaglutide has been under review for further indications including heart failure with preserved ejection fraction and peripheral artery disease. Weight reduction is a surrogate; hard cardiovascular outcomes are not, and that evidence base takes years to build.

A detail worth noticing

Weight reduction was approximately 6% lower in men than in women across both treatment arms. Sex differences of that size are rarely foregrounded in coverage of these trials, and they matter for interpreting any single reported average.

Quick reference

Endpoint (72 wks)TirzepatideSemaglutide
Mean weight change−20.2%−13.7%
Absolute weight−22.8 kg−15.0 kg
Waist circumference−18.4 cm−13.0 cm
GI discontinuation2.7%5.6%
ReceptorsGIP + GLP-1GLP-1
CV outcome trial-SELECT, 20% MACE reduction

Frequently asked questions

Which is more effective for weight reduction?

Tirzepatide, clearly, in the only large head-to-head trial: 20.2% against 13.7% over 72 weeks.

Is tirzepatide worse tolerated because it is stronger?

Not on this measure. Gastrointestinal discontinuation was lower on tirzepatide at 2.7% than semaglutide at 5.6%.

Why would anyone use semaglutide then?

It has far more cardiovascular outcome evidence, including SELECT's 20% MACE reduction across 17,604 participants, and broader approved and pending indications.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.